Health Essentials
- Home
- Blog
Blogs
- January 24, 2023
- backoffice
Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11;14) multiple myeloma
A BCL-2 inhibitor named as venetoclax which was initially given FDA approval. Proteins significantly regulate the apoptotic process from the B cell CLL or lymphoma families. Venetoclax treats some forms…
- January 24, 2023
- team
Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma
Many pediatric cancer deaths are caused by Hodgkin lymphoma which formerly known as Hodgkin’s disease. HL or Hodgkin Lymphoma is extremely rare in infants, but it is the most prevalent…
- December 14, 2022
- team
Venclyxto updated recommendations on tumor lysis syndrome (TLS)
Venclexto is frequently prescribed for cancer patients to help them administer localized cancer therapy. It is available as tablets that can be taken orally, but there are no generic Venclexto…
- December 14, 2022
- team
Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma
An antibody-drug combination called Brentuximab Vedotin, commonly known as Adcetris, combines an anti-CD30 antibody with monomethyl auristatin E. (MMAE). Brentuximab injection price in India is low compared to other countries. Additionally, Adcetris…
- November 21, 2022
- team
Kineret, a biologic drug, can prevent gout flare-ups
Gout is a prevalent type of auto-inflammatory arthritis that develops when MSU crystals accumulate in the synovial joints’ soft tissue. Acute gout flare-ups are marked by specific inflammatory symptoms such…
- November 21, 2022
- team
In older or less-fit CLL patients, first-line ibrutinib plus venetoclax improves outcomes
Ibrutinib, an oral BTK inhibitor taken once daily, is the only targeted treatment to show improved progression-free survival (PFS). Venetoclax is a single agent or combination with rituximab or obinutuzumab…